MTOR and ovarian cancer: Several inhibitors of PI3K/Akt/mTOR pathway have been clinically applied to some malignancies including ovarian cancer, and c-Met receptor has been found to promote PI3K/Akt/mTOR pathway and to play an important role in drug resistance 71.